Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Jeffrey Pu, MD, PhD

    ... stem cell (HSC) acquiring a PIG-A gene mutation . PIG-A mutations lead to the absence of ... a better response to immunosuppressive therapy; 3) PIG-A mutation significantly increased in some human cell lines with genomic ... at progenitor level and are transient. The PIG-A mutation frequency in MDS patients harboring PNH-like cells were 10 to 100 ...

    Grant Recipient last updated 10/01/2013 - 1:51pm.

  2. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.

    ... P=0.007) and SRSF2 (45.5% vs. 11.8%, P<0.001). IDH2 mutation was a poor prognostic factor for overall survival in patients with ... demonstrated that all IDH-mutated patients retained the same mutation during disease evolution while none of the IDH-wild patients acquired ...

    Research Article last updated 10/22/2013 - 12:48pm.

  3. Rosannah Cameron, PhD

    ... mutations. Our research involves using zebrafish with a mutation in a key splicing factor, sf3b1, to look at what happens to ... cells to further mutations. Our zebrafish have a mutation in a key splicing factor, sf3b1 (splicing factor 3b, subunit 1), ...

    Grant Recipient last updated 08/16/2016 - 1:17pm.

  4. A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

    ... in advanced hematologic malignancies that harbor an IDH1 mutation . Status:  ...

    Clinical Trial last updated 02/22/2017 - 11:21am.

  5. Kim-Hien T. Dao, DO, PhD

    ... from patients who inherit a loss-of-function mutation in one of the genes of the Fanconi anemia pathway are ... cells from patients who inherit a loss-of-function mutation in one of the genes of the Fanconi anemia pathway are ...

    Grant Recipient last updated 10/01/2012 - 10:46am.

  6. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases

    ... Amplicon Cancer Panel (Illumina) covering mutation hotspots of 53 genes. Overall, mutation(s) were detected in 58.6% of t-MDS/AML and 56.8% of de novo MDS/AML. ...

    Research Article last updated 03/02/2015 - 2:00pm.

  7. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

    ... in the matched MDS sample. Here we show that a missense mutation affecting the serine at codon 34 (Ser34) in U2AF1 was recurrently ... increased risk of progression to sAML associated with this mutation. U2AF1 is a U2 auxiliary factor protein that recognizes the AG splice ...

    Research Article last updated 01/09/2012 - 2:17pm.

  8. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

    ... with high risk MDS or AML treated with AZA. A TP53 mutation was found in 23 patients (37.1%), associated with complex ... OS was negatively influenced by the presence of TP53 mutation (median OS 12.4 months versus 23.7 months, p<10-4), abnormal ...

    Research Article last updated 06/02/2014 - 11:17am.

  9. Clinical effect of point mutations in myelodysplastic syndromes

    ... myelodysplastic syndromes. We then examined whether the mutation status for each gene was associated with clinical variables, ... A total of 51% of all patients had at least one point mutation, including 52% of the patients with normal cytogenetics . ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. MEDALIST Trial

    ... in bone marrow or ≥ 5% (but < 15%) if SF3B1 mutation is present. - < 5% blasts in bone marrow - ...

    Clinical Trial last updated 02/22/2017 - 11:42am.